Prospective audit of Febrile neutropenia management at a tertiary university hospital in Singapore

Annals of the Academy of Medicine Singapore

Volumn 39, Issue 6, 2010, Pages 453-459

  Jin, Jing ^a   Lee, Yee Mei ^b   Ding, Ying ^b   Koh, Liang Piu ^b   Lim, Siew Eng ^b   Lim, Robert ^b   Tambyah, Paul Ananth ^b   Hsu, Li Yang ^b  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^b NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

Author keywords

Antimicrobial resistance; Gram negative bacilli; MASCC score

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; CARBAPENEM; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; PIPERACILLIN; TAZOBACTAM; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTEREMIA; BLOOD CULTURE; CENTRAL VENOUS CATHETER; CLINICAL PROTOCOL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE DURATION; DISEASE SEVERITY; ETHNICITY; FEBRILE NEUTROPENIA; FEMALE; HIGH RISK PATIENT; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; MONOTHERAPY; MORTALITY; NEUTROPHIL COUNT; RISK ASSESSMENT; SINGAPORE; TERTIARY HEALTH CARE; UNIVERSITY HOSPITAL; FEVER; GRAM NEGATIVE BACTERIUM; MIDDLE AGED; NEUTROPENIA; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; DRUG RESISTANCE, MICROBIAL; FEMALE; FEVER; GRAM-NEGATIVE BACTERIA; HOSPITALS, UNIVERSITY; HUMANS; MALE; MEDICAL AUDIT; MIDDLE AGED; NEUTROPENIA; OUTCOME ASSESSMENT (HEALTH CARE); PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SINGAPORE; YOUNG ADULT;

EID: 77954530218     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006;106:2258-66.
2. Viscoli C. Infectious complications in neutropenic cancer patients. Available at: http://cme.medscape.com/viewarticle/468938. Accessed 30 July 2009.
3. Au E, Ang PT. Management of chemotherapy-induced neutropenic sepsis - combination of cephalosporin and aminoglycoside. Ann Acad Med Singapore 1993;22:319-22.
4. Wong GC, Tan BH. Use of antibiotics in a haematology ward - an audit. Ann Acad Med Singapore 2008;37:21-6.
5. Bow EJ. Management of the febrile neutropenic cancer patient: lessons from 40 years of study. Clin Microbiol Infect 2005;11Suppl 5:S24-9.
6. Schimpff SC, Greene WH, Young VM, Wiernik PH. Pseudomonas septicemia: incidence, epidemiology, prevention and therapy in patients with advanced cancer. Eur J Cancer 1973;9:449-55.
7. Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000;18:3038-51.
8. Uys A, Rapoport BL, Fickl H, Meyer PW, Anderson R. Prediction of outcome in cancer patients with febrile neutropenia: comparison of the Multinational Association of Supportive Care in Cancer risk-index score with procalcitonin, C-reactive protein, serum amyloid A, and interleukins- 1beta, -6, -8 and -10. Eur J Cancer Care (Engl) 2007;16:475-83.
9. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730-51.
10. Huang XJ, Shen ZX, Wang C, Reksodiputro AH, Ranuhardy D, Tamura K, et al. Clinical guidelines for the management of cancer patients with neutropenia and unexplained fever. Int J Antimicrob Agents 2005;26Suppl2:S128-32; discussion S33-40.
11. National Comprehensive Cancer Network. Prevention and treatment of cancer-related infections. Available at: http://www.nccn.org/professionals/physician_gls/PDF/infections.pdf. Accessed 30 July 2009.
12. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187-205.
13. De Pauw B, Walsh TH, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infections Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008;46:1813-21.
14. Feld R. Bloodstream infections in cancer patients with febrile neutropenia. Int J Antimicrob Agents 2008;32 Suppl1:S30-3.
15. Hsu LY, Tan TY, Jureen R, Koh TH, Krishnan P, Lin R, et al. Antimicrobial drug resistance in Singapore hospitals. Emerg Infect Dis 2007;13:1944-7.
16. Imran H, Tleyjeh IM, Arndt CA, Baddour LM, Erwin PJ, Tsigrelis C, et al. Fluoroquinolone prophylaxis in patients with neutropenia: a metaanalysis of randomized placebo-controlled trials. Eur J Clin Microbiol Infect Dis 2008;27:53-63.
17. Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 2008;353:977-87.
18. Paul M, Borok S, Fraser A, Vidal L, Cohen M, Leibovici L. Additional anti-gram-positive antibiotic treatment for neutropenic cancer patients. Cochrane Database Syst Rev 2005;3:CD003914.
19. Vidal L, Paul M, Ben dor I, Soares-Weiser K, Leibovici L. Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients: a systematic review and meta-analysis of randomized trials. J Antimicrob Chemother 2004;54:29-37.